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Many guidance receptors are proteolytically cleaved
by membrane-associated metalloproteases of the
ADAM family, leading to the shedding of their ecto-
domains. Ectodomain shedding is crucial for recep-
tor signaling and function, but how this process is
controlled in neurons remains poorly understood.
Here, we show that the transmembrane protein
Lrig2 negatively regulates ADAM-mediated guidance
receptor proteolysis in neurons. Lrig2 binds Neoge-
nin, a receptor for repulsive guidance molecules
(RGMs), and prevents premature Neogenin shedding
by ADAM17 (TACE). RGMa reduces Lrig2-Neogenin
interactions, providing ADAM17 access to Neogenin
and allowing this protease to induce ectodomain
shedding. Regulation of ADAM17-mediated Neoge-
nin cleavage by Lrig2 is required for neurite growth
inhibition by RGMa in vitro and for cortical neuron
migration in vivo. Furthermore, knockdown of Lrig2
significantly improves CNS axon regeneration.
Together, our data identify a unique ligand-gated
mechanism to control receptor shedding by ADAMs
and reveal functions for Lrigs in neuron migration
and regenerative failure.
INTRODUCTION
Leucine-rich repeats and immunoglobulin-like domains (Lrig)
proteins are unique transmembrane proteins with an extracel-
lular domain containing leucine-rich repeats (LRRs) and immu-
noglobulin-like (Ig-like) domains and a cytosolic region with no
apparent homology to other proteins (Figure 1A). The Lrig family
contains three vertebratemembers, Lrig1 (Lig1), Lrig2, and Lrig3,
whileDrosophila andCaenorhabditis elegans each contain a sin-
gle Lrig gene (Guo et al., 2004). Lrig1 is best characterized at theDevelopmfunctional level and controls the activity of several growth factor
receptors (e.g., Gur et al., 2004; Laederich et al., 2004; Ledda
et al., 2008). Lrig1 deficiency in mice leads to a variety of pheno-
types, including excess intestinal stem cell proliferation, tumor
formation, impaired auditory responses, and psoriasis-like hy-
perplasia (Del Rio et al., 2013; Page et al., 2013; Powell et al.,
2012; Suzuki et al., 2002; Wong et al., 2012). In addition, Lrig1
has been described as a tumor suppressor in humans and is
associated with tumor growth and patient survival (Lindquist
et al., 2014). Unfortunately, our understanding of the function
and mechanism of action of other Lrigs is rather rudimentary.
Further, despite prominent neuronal expression of Lrigs, how
these proteins contribute to nervous system development or
function is poorly understood.
Here, we show that Lrig2 controls the proteolytic processing of
axon guidance receptors. During embryonic development, axon
guidance proteins provide instructive signals for growing axons
and migrating neurons and are detected by cell-surface recep-
tors at the growth cone (Kolodkin and Pasterkamp, 2013).
Many axon guidance receptors are proteolytically cleaved at
their juxta-membrane region by membrane-associated metallo-
proteases of the ADAM (A disintegrin and metalloprotease) fam-
ily, leading to the shedding of their ectodomains. This shedding
is required for proper axon guidance and controls receptor
levels, activation, and the disassembly of ligand-receptor com-
plexes (Bai and Pfaff, 2011). Despite these important roles,
how the neuronal effects of ADAMs are controlled to regulate
axon guidance receptor signaling remains incompletely under-
stood. For example, shedding of Neogenin, a receptor for repul-
sive guidance molecule a (RGMa) (Matsunaga et al., 2004;
Monnier et al., 2002; Rajagopalan et al., 2004) by ADAM17 de-
sensitizes axons to RGMa, but how this cleavage event is initially
prevented to allow cleavage only after ligand binding is unknown
(Okamura et al., 2011). Thus, unidentified regulatory mecha-
nisms are in place to control ADAM17-mediated Neogenin
cleavage in neurons.
In this study, we identify Lrig2 as a binding partner of Neogenin
and show that Lrig2 prevents the premature shedding of Neoge-
nin by ADAM17 in an RGMa-dependent manner. This regulatoryental Cell 35, 537–552, December 7, 2015 ª2015 Elsevier Inc. 537
Figure 1. Expression of Lrig2 during Neural Development
(A) The Lrig family in vertebrates. ECD, extracellular domain; ICD, intracellular domain; Ig, immunoglobulin; LRR, leucine-rich repeat.
(B) In situ hybridization for Lrig1, Lrig2, or Lrig3 on coronal (upper panels) and sagittal (lower panels) sections from E16.5mouse embryos. CP, cortical plate; DRG,
dorsal root ganglion; Hip, hippocampus; STR, striatum; VZ, ventricular zone.
(legend continued on next page)
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mechanism is required for the axon growth inhibitory effects of
RGMa-Neogenin signaling in vitro. In line with this observation
and with the regeneration-inhibiting effect of RGMa (Hata
et al., 2006), knockdown of Lrig2 significantly promotes optic
nerve regeneration in vivo. Finally, we show that regulation of
ADAM17-mediated cleavage of Neogenin by Lrig2 controls
neuronal migration in the embryonic cortex in vivo. These data
reveal a neuronal role for Lrigs and unveil a previously uncharac-
terized mechanism in ADAM regulation that prevents premature
receptor cleavage while retaining ligand responsiveness.
RESULTS
Expression of Lrigs in the Developing Nervous System
HowLrig proteins contribute to CNSdevelopment remains unex-
plored. To address this question, we determined neural Lrig
expression patterns using in situ hybridization. All three Lrigs
were detected in the developing mouse brain and spinal cord,
displaying clearly distinct patterns of expression (Figures 1B
and S1). Expression of Lrig1 was strong in the ventricular zones
of the embryonic nervous system, while at postnatal day 9 (P9),
Lrig1was detected in differentiated neurons. Lrig2 and Lrig3 dis-
played overlapping patterns of expression, but Lrig2 was more
widespread and several structures showed Lrig2 but no Lrig3
labeling (Figures 1B and S1). This pattern of neural Lrig expres-
sion was confirmed by immunohistochemistry at embryonic
day E16.5. Lrig1 prominently labeled ventricular regions. Lrig2
was strongly expressed throughout the brain, while many
Lrig2-positive areas did not show Lrig3 labeling (Figures 1C,
S2, S3A, and S3B). Of all three Lrigs, Lrig2 was most abundantly
expressed in post-mitotic neurons. Therefore, to begin to dissect
the role of Lrigs during CNS development, we focused on Lrig2.
Lrig2Binds theGuidanceReceptor Neogenin inNeurons
Further characterization of Lrig2 expression by immunocyto-
chemistry on dissociated cortical neurons revealed strong
expression in the cell body and punctate staining in neurites
and growth cones (Figure 1D), suggesting a role for Lrig2 in
axon growth and guidance. As a first step toward determining
the function of Lrig2, we used a biotin-streptavidin-based
purification method to identify Lrig2-interacting proteins (Fig-
ures 1E and 1F) (Groen et al., 2013). This system allowed
for highly specific pull-down of biotinylated full-length Lrig2
using streptavidin-coated beads (Figure 1G). Silver staining
revealed multiple specific Lrig2-interacting proteins (Figure 1G),
and mass spectrometry analysis of the pull-down samples
identified many proteins that were present specifically in
Lrig2-GFP-Bio complexes. Interestingly, several of the candi-(C) Immunohistochemistry for Lrig2 in coronal sections of an E16.5 mouse embr
OE, olfactory epithelium.
(D) E14.5 mouse cortical neuron cultures analyzed at 3 days in vitro (DIV) by imm
panels show a higher magnification of the boxed areas in the left panels.
(E) Biotin- and GFP-tagged Lrig2 construct used in the pull-down experiments in
(F) Biotin-streptavidin pull-down assay. Lrig2-GFP-Bio or Bio-GFP are biotinylat
streptavidin-coated beads, along with interacting proteins. Purple region indicat
(G) Streptavidin pull-down assays on lysates of HEK293 cells co-expressing Bio
analyzed by western blotting using anti-GFP antibodies (left panel). The same sam
Dots indicate Lrig2-GFP-Bio and Bio-GFP, and arrow indicates endogenous Neo
Scale bars represent 500 mm (B), 100 mm (C), and 20 mm (D). See also Figures S
Developmdate interactors had reported roles in axon growth and
guidance, cytoskeletal organization, and intracellular transport
(Table S1).
One of the candidate interactors was Neogenin, a cell-surface
receptor for RGMs, bone morphogenetic proteins (BMPs), and
Netrins. In the nervous system, Neogenin has been best
characterized as a growth cone receptor for RGMa (Figure 2A).
To examine whether Lrig2 contributes to RGMa-Neogenin
signaling, we first confirmed the interaction between Neogenin
and Lrig2 in HEK293 cells transiently overexpressing full-length
Neogenin (NeoFL-GFP-Bio) or the Neogenin intracellular domain
(ICD; Bio-GFP-NeoICD). Endogenous Lrig2 was detected
following pull-down of NeoFL-GFP-Bio, but not of Bio-GFP-
NeoICD. In contrast, Myosin-X, which is known to interact with
the Neogenin ICD (Zhu et al., 2007), co-precipitated with full-
length Neogenin and the Neogenin ICD (Figure 2B). Next, we
performed co-immunoprecipitation experiments from N1E-115
neuronal cell lysates and P0 brains using Neogenin- and Lrig2-
specific antibodies. Endogenous Lrig2 co-precipitated with
endogenous Neogenin from neuronal cell lysates, and vice versa
(Figures 2C, 2D, and S3C). Similarly, pull-down of Neogenin from
P0 brain lysates resulted in co-precipitation of Lrig2 (Figure 2E).
The interaction between Lrig2 and Neogenin in brain tissue
suggests that these proteins co-localize in neurons. Indeed,
immunohistochemistry revealed that at E16.5, the majority of
neurons in thecortexandasubset of cortical axons in theexternal
capsule co-expressed Neogenin and Lrig2 (Figures 2F–2K).
Furthermore, immunostaining of dissociated cortical neurons
for Neogenin and Lrig2 overlapped, but vesicular structures ex-
pressing Neogenin, but not Lrig2, and vice versa, were also
observed (Figures 2L–2Q). Together, these results show that
Lrig2 and Neogenin interact and partly co-localize in neurons.
Neogenin and Lrig2 Interact through Their Extracellular
Domains
To further define the interaction between Neogenin and Lrig2, a
series of truncation mutants was generated (Figures S4A and
S4B) and used in pull-down assays. Lrig2 constructs containing
the LRR and/or Ig-like domains showed binding to Neogenin, but
binding of the Lrig2 Ig-like region (Lrig2-DLRR) to Neogenin was
more robust as compared to Lrig2-LRR-Neogenin binding (Fig-
ures S4C and S4E). The Neogenin ICD region did not interact
with Lrig2 (Figure 2B), but Neogenin proteins containing the Ig-
like and/or fibronectin type III (FN) regions bound Lrig2 (Figures
S4D and S4F). To further dissect these interactions, we carried
out surface plasmon resonance (SPR) equilibrium binding exper-
iments. Our analysis revealed that the full-length ectodomain of
Lrig2 (Lrig2-ECD) bound to full-length Neogenin ectodomainyo (green). DAPI in blue (lower panels). LP, lamina propria; MZ, marginal zone;
unocytochemistry using anti-Lrig2 antibodies. Phalloidin staining in red. Right
(G).
ed by the co-transfected biotin ligase BirA and purified by precipitation using
es full-length Lrig2.
-GFP or Lrig2-GFP-Bio and BirA. Proteins bound to streptavidin beads were
ples were separated on a gradient gel followed by silver staining (right panel).
genin.
1–S3 and Table S1.
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Figure 2. Lrig2 Binds and Co-localizes with
the RGMa Receptor Neogenin in Neurons
(A) Neogenin and its ligand RGMa (repulsive
guidance molecule a). ECD, extracellular domain;
FN, fibronectin type III; Hydro, hydrophobic
domain; ICD, intracellular domain; Ig, immuno-
globulin; RGD, Arg-Gly-Asp; vWF, partial von Wil-
lebrand factor type D.
(B) Streptavidin pull-down assays were performed
on lysates of HEK293 cells co-transfected with the
indicated constructs and BirA. Co-immunopre-
cipitated proteins were analyzed by western blot-
ting using the indicated antibodies. Myosin X is a
known Neogenin interactor.
(C and D) Lysates of N1E-115 cells were immu-
noprecipitated with anti-IgG (control), anti-Lrig2
(C), or anti-Neogenin (D) antibodies. The immuno-
precipitates were analyzed with the indicated
antibodies. Figure S3C shows full-size western
blots.
(E) P0 mouse brain lysate was immunoprecipitated
with anti-IgG and anti-Neogenin antibodies. The
precipitates were analyzed with the indicated
antibodies. Figure S3C shows full-size western
blots.
(F–K) Immunohistochemistry for Neogenin (red)
and Lrig2 (green) on E16.5 coronal mouse brain
sections. (I)–(K) show higher magnifications of the
boxed area in (F). Nissl is in blue. Arrows indicate
co-expression of Lrig2 and Neogenin in cortical
neurons. CP, cortical plate; EC, external capsule;
MZ, marginal zone.
(L–Q) Immunocytochemistry for Neogenin (red)
and Lrig2 (green) on E14.5 dissociated cortical
neurons at DIV3. (O)–(Q) show higher magnifica-
tions of the boxed area in (L). Arrows indicate areas
of co-expression.
All data represent at least three independent ex-
periments. Scale bars represent 100 mm (F–K) and
20 mm (L–Q). See also Figure S3C.(Neo-ECD) as well as Neogenin FN1–6 (Neo-FN1–6), but not to
the Neo Ig1–4 domains (Neo-IG1–4) (Figure S4G). Lrig2-IG1–3
bound Neo-ECD and Neo-FN1–6, but Lrig2-LRR-IG1 did
not show any binding to Neo-ECD (Figures S4H and S4I).
This suggests that the two membrane-proximal Lrig2 Ig-like
domains (IG2-3) and the six membrane-proximal Neogenin
FN domains form the major interaction site in the Neogenin-
Lrig2 complex. We had previously shown that the Neo-FN5-6
domains are the key interaction site for all human RGM family
members (Bell et al., 2013). Interestingly, we observed binding
in lowmicromolar range for Lrig2-IG1–3:Neo-FN5-6 (Figure S4J),540 Developmental Cell 35, 537–552, December 7, 2015 ª2015 Elsevier Inc.but no binding for Lrig2-LRR-IG1:Neo-
FN5-6 (Figure S4K). Finally, COS-7 cell
binding assays were performed to deter-
mine whether the Neogenin ligand
RGMa binds Lrig2. Strong binding of alka-
line phosphatase (AP)-tagged RGMa
(RGMa-AP) was observed in Neogenin+,
but not Lrig2+, cells (Figure S4L).
Together, our data indicate that the mem-
brane-proximal Neo FN5-6 domains arecrucial for Lrig2 binding and that RGMa binds Neogenin, but
not Lrig2 (Figure S4M).
Lrig2 Is Required for RGMa-Neogenin-Mediated
Signaling and Neurite Growth Inhibition
Binding of RGMa to Neogenin induces growth cone collapse and
neurite growth inhibition. To determine whether Lrig2 is required
for these effects, we knocked down Lrig2 in dissociated cortical
neurons and performed growth cone collapse and CHO layer as-
says. Acute exposure of cortical neurons to RGMa induced
growth cone collapse, but this effect was not observed following
Figure 3. Lrig2 Is Required for RGMa-
Induced Neurite Growth Inhibition and
Signaling
(A) Immunocytochemistry for GFP in growth
cones. Dissociated P0 cortical neurons were
transfected with GFP vector and siRNAs (siScr or
siLrig2) and exposed to RGMa ligand or control
at 3 DIV.
(B) Graph shows percentage of growth cone
collapse in RGMa-stimulated and control neurons.
n = 2 experiments, >100 neurons per condition per
experiment. *p < 0.05, Student’s t test.
(C) Dissociated E14.5 cortical neurons were elec-
troporated with GFP vector and combinations of
the indicated vectors and grown on confluent CHO
cell layers. RS is a rescue construct that is not
targeted by shLrig2. At 4 DIV, cultures were fixed
and immunostained with anti-GFP antibodies.
Lower panels show tracing of the longest neurite in
each example. EV, empty vector.
(D) Quantification of neurite length in cultures as
in (C). Graphs show average length of the longest
neurite normalized to control (shScr+EV on CHO-
Control cells). n = 3 experiments, >50 neurons per
condition per experiment. *p < 0.05, two-way
ANOVA.
(E) E18 cortical neurons electroporated with siScr
or siLrig2 were incubated with 2 mg/ml RGMa or
control protein (BSA) at DIV3. Cell lysates were
subjected to active RhoA pull-down assays, and
cell lysates and pull-down samples were analyzed
by western blotting using anti-RhoA antibodies.
(F) Quantification of band intensities in experi-
ments as shown in (E). Signals from active RhoA
bands were compared to those of total RhoA in
each lane. Results are shown as fold change
relative to control. *p < 0.05, one-way ANOVA fol-
lowed by Tukey-Kramer’s test.
All data are presented as means (of three or more
independent experiments) ± SEM. Scale bars
represent 10 mm (A) and 50 mm (C). See also Fig-
ures S5A–S5E.Lrig2 knockdown (Figures 3A, 3B, and S5A–S5C). CHO assays,
in which neurons are plated on a confluent layer of RGMa-ex-
pressing or control CHO cells (CHO-RGMa or CHO-Control),
are used to study the neurite growth inhibitory effect of RGMa.
Dissociated E14.5 mouse cortical neurons were electroporated
with expression vectors containing shLrig2 or scrambled control
small hairpin RNA (shRNA) (shScr) in combination with GFP and
either empty vector or Lrig2-RS, a rescue construct that is not
targeted by shLrig2 (Figures S5A–S5D). Neurite outgrowthDevelopmental Cell 35, 537–552,from cortical neurons electroporated
with shScr and empty vector (EV) was
significantly reduced on CHO-RGMa as
compared to CHO-Control cells (Figures
3C and 3D). However, knockdown of
Lrig2 significantly reduced RGMa’s inhib-
itory effect. Co-electroporation of shLrig2
and Lrig2-RS restored the sensitivity of
neurites to RGMa, while electroporation
of Lrig2-RS alone had no effect (Figures3C and 3D). Thus, Lrig2 is required for RGMa-induced growth
cone collapse and neurite growth inhibition.
Binding of RGMa to Neogenin induces activation of RhoA
(Conrad et al., 2007; Hata et al., 2009). To query a role for Lrig2
in RGMa-dependent RhoA activation, Lrig2 was knocked down
in mouse cortical neuron cultures and Rho activation was deter-
mined by affinity precipitation of GTP-bound RhoA. As reported
previously, addition of 2 mg/ml RGMa for 15 min to cultures elec-
troporated with control small interfering RNAs (siRNAs) (siScr)December 7, 2015 ª2015 Elsevier Inc. 541
Figure 4. Lrig2 Regulates Neogenin Cell-Surface Expression at the Growth Cone
(A) Immunocytochemistry for intracellular GFP and cell-surface Neogenin expression in E14.5 cortical neuron growth cones transfected with siRNAs at 1 DIV and
analyzed at 3 DIV.
(B) Quantification of growth cone fluorescent intensity as in (A). Data are normalized to siScr control. n = 3 experiments, >60 growth cones per condition per
experiment. **p < 0.01, Student’s t test.
(C) Endogenous surface proteins of N1E-115 cells transfected with pSuper-shScr or pSuper-shLrig2 were biotinylated on ice. Biotin-labeled surface proteins
were pulled down using streptavidin-coated beads and subjected to western blotting.
(D) Quantification of band intensities as in (C). Neogenin surface levels are normalized to control. *p < 0.05, Student’s t test.
(E–J) Immunohistochemistry for Lrig2 (green) and ADAM17 (red) in E16.5 coronal sections. (H)–(J) show higher magnifications of the boxed area in (E). Nissl is in
blue. CP, cortical plate; MZ, marginal zone.
(legend continued on next page)
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led to a 2-fold increase in Rho activity. No RGMa-induced in-
crease in Rho activity was observed following knockdown of
Lrig2 (siLrig2; Figures 3E, 3F, and S5E). Thus, Lrig2 is required
for signaling downstream of RGMa-Neogenin.
Lrig2 Regulates Neogenin Cell-Surface Expression
The next question we addressed was how Lrig2 influences
RGMa-Neogenin signaling. A well-characterized effect of Lrigs
is their ability to induce receptor ubiquitination and degradation.
However, knockdown of Lrig2 did not change Neogenin protein
levels in total neuronal cell lysates or Neogenin expression in pri-
mary cortical neurons (Figures S6A–S6C). Other previously re-
ported effects of Lrigs, such as lipid raft recruitment, were also
unchanged for Neogenin following Lrig2 knockdown (data not
shown).
The cell-surface levels of axon guidance receptors are tightly
controlled to dictate signaling duration, magnitude, and spatial
activity. Therefore, we next explored the effect of Lrig2 on
Neogenin cell-surface expression. Dissociated cortical neurons
were transfected at DIV1 with siRNAs together with GFP and
immunolabeled with antibodies against Neogenin at DIV3 under
non-permeabilizing conditions. A significant decrease in Neoge-
nin surface intensity was observed in neurons transfected with
siLrig2 as compared to siScr (Figures 4A and 4B). In addition,
cell-surface biotin labeling experiments in neuronal cells
demonstrated a reduction in Neogenin cell-surface expression
following Lrig2 knockdown (Figures 4C and 4D). These data un-
veil a role for Lrig2 in the regulation of Neogenin cell-surface
expression.
Lrig2 Negatively Regulates ADAM17-Mediated
Cleavage of Neogenin
Both Neogenin and Lrig2 are expressed in vesicular structures in
the growth cone, which may represent exocytotic or endocytotic
vesicles (Figures 2L–2Q). Defects in exocytosis or endocytosis
could explain the reduction in Neogenin cell-surface expression
observed following Lrig2 knockdown. However, Lrig2 knock-
down did not affect internalization of Neogenin as assessed
by anti-Neogenin antibody internalization and cell-surface
biotinylation experiments (Figures S6D–S6G). In addition, fluo-
rescence recovery after photobleaching (FRAP) of pHLuorin-
Neogenin was intact following Lrig2 knockdown (Figures S5F,
S6H, and S6I). These data suggest that exo-endocytic recycling
of Neogenin is independent of Lrig2.
ADAM17 cleaves and sheds the Neogenin ECD at the growth
cone membrane and desensitizes cortical neurons to the repul-
sive effects of RGMa (Goldschneider et al., 2008; Okamura et al.,
2011). Therefore, a possible explanation for the effect of Lrig2 on
Neogenin cell-surface expression is that Lrig2 negatively regu-
lates Neogenin ectodomain shedding. If so, Lrig2 knockdown
would induce enhanced shedding and reduce Neogenin cell-
surface expression. To test this hypothesis, we first confirmed
that Lrig2 and ADAM17 co-localize in embryonic cortical neu-(K) Immunocytochemistry for intracellular GFP and cell-surface Neogenin express
and cultured with vehicle (DMSO) or TAPI-1.
(L) Quantification of growth cone fluorescent intensity as in (K). Data were norma
experiment. **p < 0.01, Student’s t test.
All data are presented asmeans (of three or more independent experiments) ± SEM
Developmrons (Figures 4E–4J). Next, dissociated cortical neurons were
transfected with siRNAs and cultured in the presence of
TAPI-1, an inhibitor of ADAM17 and other metalloproteases, or
vehicle. Knockdown of Lrig2 induced a significant decrease in
cell-surface Neogenin expression, but this effect was not
observed in the presence of TAPI-1 or following ADAM17 knock-
down (Figures 4K, 4L, and 6H). This suggests that Lrig2 normally
negatively regulates Neogenin shedding by ADAM17. To further
implicate Lrig2 in Neogenin shedding, HEK293 cells were trans-
fected with Neogenin-GFP-Bio and a combination of ADAM17
and/or Lrig2 expression constructs. ADAM17-mediated Neoge-
nin cleavage was reduced by co-transfection of full-length Lrig2
or the Lrig2 ECD, but not by the Lrig2 ICD (Figures 5A, 5B, and
5D). These data show that the Lrig2 ECD blocks ADAM17-
induced cleavage of Neogenin.
The activity of ADAM17 is regulated through extra- and intra-
cellular mechanisms. Lrig2 binds the ECD of Neogenin, and
the Lrig2 ECD is sufficient to block cleavage of Neogenin. This
suggests that Lrig2 is an extracellular regulator of ADAM17. To
provide further support for this model, we incubated lysates of
HEK293 cells transfected with Neogenin-GFP-Bio and empty
vector (EV) or Lrig2-FL with recombinant ADAM17 extracellular
domain (r-ADAM17). Addition of r-ADAM17, but not other
ADAMs such as ADAM9 or ADAM10 (Figure S6J), enhanced
Neogenin cleavage. As predicted, this effect was not observed
in the presence of Lrig2 (Figures 5C and 5E). Because Lrig2
and ADAM17 interact with the Neogenin ECD, we hypothesized
that Lrig2 may interfere with ADAM17-Neogenin binding. Pull-
down of Neogenin from neuronal membrane fractions resulted
in co-precipitation of Lrig2 and confirmed that Lrig2 and Neoge-
nin interact at the membrane where ADAM17-mediated cleav-
age occurs (Figure 5F). Furthermore, Lrig2 effectively reduced
binding between Neogenin and ADAM17 in ELISAs (Figure 5G).
These data suggest that binding of Lrig2 to Neogenin prevents
this guidance receptor from interacting with ADAM17.
We next asked how binding of Lrig2 to Neogenin is regulated
to allow Neogenin shedding. To address this question, neuronal
cells were treated with RGMa-His in combination with TAPI-1 or
DMSO vehicle. Conditioned medium was collected from the
cells and immunoprecipitated using antibodies directed against
the Neogenin ECD. Incubation with RGMa-His increased the
amount of Neogenin ECD in the medium, and this effect was
nullified by addition of TAPI-1 (Figures 5H and 5I). These results
suggest that ectodomain shedding of Neogenin is ligand (RGMa)
dependent. A possible explanation for this result is that RGMa in-
duces a reduction in the interaction between Lrig2 and Neoge-
nin, providing ADAM17 access to Neogenin. In line with this
model, Neogenin-Lrig2 binding was significantly reduced in the
presence of RGMa, while Lrig2 and Neogenin levels were unaf-
fected (Figures 5J and 5K). Finally, to examine whether regula-
tion of shedding by Lrig2 contributes to RGMa-Neogenin
signaling at the functional level, dissociated cortical neurons
were electroporated with shLrig2 or shScr and cultured onion in growth cones of E14.5 cortical neurons transfected with siRNAs at 1 DIV
lized to siScr control. n = 3 experiments, >60 growth cones per condition per
. Scale bar represents 10 mm (A, E, and K). See also Figures S5E, S5F, and S6.
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Figure 5. Lrig2 Inhibits Cleavage of Neogenin by ADAM17
(A) Neogenin can be proteolytically processed by ADAM17 and g-secretase, leading to protein fragments of the indicated size. Arrowhead and arrow are used in
(B) and (C) to indicate these fragments.
(B) Streptavidin pull-down assays on lysates of HEK293 cells co-expressing the indicated constructs together with BirA. Proteins bound to streptavidin beads
were analyzed by western blotting using the indicated antibodies. ECD, extracellular domain; FL, full-length; ICD, intracellular domain.
(legend continued on next page)
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confluent CHO cells in the presence of TAPI-1 or vehicle or in
combination with ADAM17 knockdown. Neurons grown on
CHO-RGMa cells had significantly shorter neurites, and knock-
down of Lrig2 restored neurite length toward control levels.
This effect of Lrig2 knockdown was rescued by treatment with
TAPI-1 or by ADAM17 knockdown (Figures 6A, 6B, and S5G).
These results show that regulation of ADAM17-mediated Neoge-
nin ectodomain shedding by Lrig2 is required for neurite growth
inhibition by RGMa.
Lrig2 Is Required for Cortical Neuron Migration
RGMa acts as an axon guidance protein in chick and Xenopus,
and RGMa and Neogenin regulate neuronal migration in mice
(Metzger et al., 2007; O’Leary et al., 2013). Analogous to axons,
migrating neurons have a long leading process tipped by a
growth cone-like structure, which detects extracellular cues.
During development of the cortex, pyramidal neurons migrate
from the ventricular zone (VZ) to the more superficial cortical
plate (CP) to differentiate and establish functional connections
(Figure 6C). Our immunohistochemical studies show that Lrig2,
Neogenin, and ADAM17 are expressed in migrating cortical neu-
rons (Figures 2 and 4). To determine the role of Lrig2 and Neoge-
nin during cortical neuron migration, shRNA vectors together
with GFP were targeted to neuronal progenitors in the VZ by in
utero electroporation (IUE) at E14.5 followed by immunohisto-
chemical characterization of the neurons that derived from these
progenitors. At E16.5, scrambled control shScr+ neurons were
primarily found in the intermediate zone (IZ) (Figure 6D). In
contrast, knockdown of Lrig2 or Neogenin caused an increase
in the percentage of neurons found in the VZ/subventricular
zone (SVZ) and CP and a corresponding decreased percentage
of neurons in the IZ. These phenotypes were not observed when
shRNAswere co-electroporated with their corresponding rescue
constructs (Figures 6D, 6E, and S5H). These data, coupled with
RGMa expression in the VZ and CP (Figure S7A) and the ability
of RGMa to repel migrating neurons, suggest that RGMa-
Neogenin-Lrig2 signaling propels migrating neurons out of the
VZ/SVZ and prevents their premature entry into the CP. To
further functionally link Lrig2 and Neogenin, we combined
knockdown of Lrig2 with overexpression or knockdown of Neo-
genin. Lrig2 knockdown triggers uncontrolled cleavage of Neo-
genin by ADAM17, leading to RGMa insensitivity (Figures 4,(C) Lysates of HEK293 cells transfected with the indicated constructs were incuba
western blot analysis. Arrowhead indicates ADAM17-induced Neogenin fragmen
(D) Quantification of band intensities as in (B). Ratio between cleaved (frag; 80 kDa
(E) Quantification of band intensities as in (C). Ratio between full-length and c
normalized to control. **p < 0.01, one-sample t test.
(F) P0 mouse brain membrane fractions were subjected to immunoprecipitatio
(Sema6A) was used as a negative control.
(G) ELISAs detected a concentration-dependent increase in binding of Neogenin
contrast, no significant increase in Neo binding was observed following additio
ADAM17 (data not shown). **p < 0.01 (Neo/ADAM17/BSA versus Neo/BSA), one
(H) N1E-115 cells were incubatedwith BSA control or 2 mg/ml RGMa-His with vehic
anti-Neogenin immunoprecipitates from conditioned N1E-115 cell medium (CM)
(I) Quantification of band intensities as in (H). Levels of cleaved Neogenin were n
(J) Immunoprecipitation of Neogenin from lysates of N1E-115 cells treated with F
the indicated antibodies.
(K) Quantification of band intensities as in (J). Ratio between Lrig2 and Neogen
control. **p < 0.01, Student’s t test.
All data are presented as means (of three or more independent experiments) ± S
Developm6A, and 6B). We predicted that expression of exogenous Neoge-
nin would restore Neogenin cell-surface expression due to the
limited capacity of endogenous ADAM17 to cleave excess Neo-
genin. Indeed, combined transfection of shLrig2 and a Neogenin
expression vector increased Neogenin cell-surface expression
as compared to shLrig2 alone (Figure 6H). Furthermore, no de-
fects in neuron migration were detected following co-electropo-
ration of shLrig2 and Neogenin (Figures 6D and 6F). shNeo or
shLrig2 induce highly similar changes in cortical neuron migra-
tion. If Lrig2 primarily acts through Neogenin in migrating
neurons, then defects observed following single or combined
knockdown of Lrig2 and Neogenin should to be comparable.
Indeed, the percentages of ectopic cells observed following
IUE of shLrig2, shNeo, or shLrig2+shNeo were similar (Figures
6D and 6F). Thus, Lrig2 acts through Neogenin to regulate
cortical neuron migration.
Next, we determined the contribution of ADAM17. Knockdown
of ADAM17 in dissociated cortical neurons leads to prolonged
Neogenin signaling and enhanced RGMa sensitivity (Okamura
et al., 2011). Neogenin knockdown induces a marked decrease
in endogenous Neogenin levels, but residual Neogenin expres-
sion can usually be detected (Figure S7B). Thus, we wanted to
knowwhether knockdown of ADAM17 could potentiate these re-
sidual Neogenin molecules and thereby partially restore the
migration defects. IUE of shNeo+siADAM17 caused a small
but significant decrease in the number of ectopic neurons, as
compared to shNeo. siADAM17 alone mildly inhibited neuronal
migration into the CP, but this effect was too small to
account for the reduction in ectopic neurons observed following
IUE of shNeo+siADAM17 (Figures 6D and 6G). Next, we com-
bined knockdown of Lrig2 and ADAM17. shLrig2+siADAM17
increased Neogenin cell-surface expression in cortical neurons
in vitro, while in vivo it restored the normal distribution of
migrating neurons (Figures 6D, 6G, and 6H). Together, our data
indicate that Lrig2 regulates ADAM17-mediated cleavage of
Neogenin to control neuronal migration in the developing cortex.
Knockdown of Lrig2 Promotes CNS Axon Regeneration
RGMa contributes to the axon growth inhibitory environment of
the injured mammalian CNS, and intrathecal application of
RGMa antibodies promotes axon regeneration after rat spinal
cord injury (Hata et al., 2006). To test whether Lrig2 manipulationted at 37Cwith or without recombinant ADAM17 (r-ADAM17) and subjected to
t and arrow indicates fragment produced by g-secretase cleavage.
) and full-length Neogenin (flNeo) was calculated. *p < 0.05, one-sample t test.
leaved Neogenin was calculated in r-ADAM17 experiments, and data were
n with the indicated antibodies followed by western blotting. Semaphorin6A
-ECD (Neo) to wells coated with recombinant ADAM17 (Neo/ADAM17/BSA). In
n of excess Lrig2 ECD (5.0 mg/ml; Neo/ADAM17/Lrig2). Lrig2 does not bind
-way ANOVA followed by Scheffe’s multiple comparison test.
le (DMSO) or TAPI-1.Western blot analysis was performed on cell lysates or on
.
ormalized to control. **p < 0.01, Student’s t test.
c control or 2 mg/ml RGMa-Fc protein. Immunoprecipitates were analyzed with
in bands was calculated in pull-down samples, and data were normalized to
EM.
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could affect axon regeneration, we used the optic nerve crush
model. siRNAs can be efficiently targeted to adult retinal gan-
glion cells (RGCs), and optic nerve regeneration can be reliably
quantified. Further, recent work shows that removal of Neogenin
from lipid rafts promotes regeneration of RGC axons following
optic nerve injury (ONI) (Tassew et al., 2014). We first used immu-
nohistochemistry to detect Neogenin expression in RGCs in the
uninjured adult mouse retina and at 14 days after ONI. Neogenin
was found in both intact and injured RGCs (Figures 7A and 7B).
Next, we induced knockdown of Neogenin in the eye by intravi-
treal injection of siRNAs targeting Neogenin (siNeo) in combina-
tion with ONI (Figure 7C). Following electroporation of scrambled
control siRNAs, most cholera toxin subunit B (CTB)-labeled RGC
axons stopped abruptly at the crush site and few fibers crossed
the lesion into the distal nerve. In contrast, siNeo induced signif-
icant regeneration beyond the lesion site and more pronounced
sprouting in the distal segment of the nerve (Figures 7D, 7E, and
S7B). Next, we determined whether knockdown of Lrig2 in RGCs
would also promote optic nerve regeneration. Immunohisto-
chemistry revealed expression of Lrig2 in intact and injured adult
mouse RGCs, and qPCR confirmed Lrig2 knockdown efficiency
following intravitreal siLrig2 injection (Figures 7B and S7C). In
stark contrast to the siScr condition, knockdown of Lrig2 in
RGCs with two different siRNAs induced pronounced regenera-
tion of numerous CTB-labeled RGC axons beyond the lesion site
and into the distal nerve (Figures 7D, 7F, and S7). To ask whether
Lrig2 acts through Neogenin to inhibit axon regeneration, we
combined siLrig2#1 with Neogenin overexpression analogous
to our approach in IUE experiments (Figure 6D). Overexpression
of Neogenin alone mildly inhibited axon regeneration, but this
effect was too small to explain the strong reduction in siLrig2-
induced axon regeneration following co-electroporation of
siLrig2#1 with Neogenin (Figures 7F, S7D, and S7G). Finally,
we combined knockdown of Lrig2 and ADAM17 to determine
whether ADAM17 contributes to the inhibitory effect of Lrig2 on
regenerating axons. Immunohistochemistry showed expression
of ADAM17 in intact and injured RGCs, and qPCR confirmed
ADAM17 knockdown efficiency following intravitreal siADAM17
injection (Figures 7B, S7E, and S7F). ADAM17 knockdown had
a small but significant inhibitory effect on axon regeneration by
itself, but when combined with siLrig#1, it restored regeneration
inhibition to control levels (Figures 7D and 7F). These data showFigure 6. Regulation of ADAM17-Mediated Shedding of Neogenin by L
(A and B) Dissociated E14.5 cortical neurons were electroporated with GFP vect
CHO cell layers with vehicle or TAPI-1. At DIV4, cultures were immunostained w
each example. Graphs in (B) show average length of the longest neurite on CHO-
control (shScr on CHO-Control cells). n = 3 experiments, >75 neurons per condi
(C) Embryonic cortical neurons express Lrig2, Neogenin (Neo), and ADAM17 a
quantification of cell migration are shown at the right. RGMa is expressed in the
subventricular zone; VZ, ventricular zone.
(D) E14.5 mouse brains were in utero electroporated with GFP vector and (comb
immunostained with anti-GFP antibodies.
(E–G) Quantification of the number of GFP-positive neurons at different positions (
symbols in boxed area besides each graph indicate significance. Statistical analys
Data represent percentage of total.
(H) Immunocytochemistry for intracellular GFP and cell-surface Neogenin expres
siRNAs and DNA vectors at 1 DIV and fixed at DIV3.
All data are presented as means (of three or more independent experiments) ± SE
S5 and S7.
Developmthat Lrig2 cooperates with Neogenin and ADAM17 to hamper
CNS regeneration.
The observation that Neogenin overexpression can only
partially inhibit the regeneration promoting effect of Lrig2 knock-
down suggested that Lrig2 may regulate multiple different pro-
teins to inhibit optic nerve regeneration. Therefore, we tested
the hypothesis that Lrig2-mediated regulation of ADAM17 prote-
olysis is amore general mechanism.We tested the ability of Lrig2
to negatively regulate cleavage of two other ADAM17 substrates,
neural cell adhesion molecule 1 (NCAM1) and Semaphorin 4D
(Sema4D), after we confirmed their ability to bind Lrig2 (Fig-
ure 7G). Interestingly, cleavage of NCAM1-GFP by ADAM17
was reduced by co-expression of Lrig2 (Figure 7H). Similarly,
Lrig2 reduced ADAM17-induced cleavage of FLAG-tagged
Sema4D (Figure 7I). These data suggest that Lrig2 may nega-
tively regulate the ADAM17-dependent processing of multiple,
distinct cell-surface proteins.
DISCUSSION
Neural circuit development and regeneration depend on the pre-
cise regulation of guidance receptors at the plasma membrane.
Different mechanisms control guidance receptor expression,
including proteolysis by ADAM proteases. However, how cleav-
age of guidance receptors by ADAMs is spatiotemporally
regulated to control receptor signaling in neurons remains incom-
pletely understood. Here, we show that Lrig2 binds the RGMa re-
ceptor Neogenin and negatively regulates Neogenin ectodomain
shedding by ADAM17. Regulation of ADAM17-mediated Neoge-
nin shedding by Lrig2 is required for the repulsive effects of
RGMa-Neogenin signaling on growing axons in vitro, and on
migrating cortical neurons in vivo. Further, in line with the inhibi-
tory effect of RGMa on axon regeneration, knockdown of Lrig2
promotes optic nerve regeneration. Together, our data unveil a
uniquemechanism for ADAM regulation that acts at the substrate
level to control premature receptor shedding while retaining
ligand responsiveness. In addition, our findings identify Lrig2 as
a potential target for promoting axon regeneration.
Negative Regulation of Ectodomain Shedding by Lrig2
Shedding of guidance receptors by ADAMs regulates receptor
cell-surface expression, activation of downstream signaling,rig2 Controls Cortical Neuron Migration
or and combinations of the indicated vectors/siRNAs and grown on confluent
ith anti-GFP antibodies. Lower panels in (A) show tracing of longest neurite in
Control cells (upper panel) or on CHO-RGMa cells (lower panel) normalized to
tion per experiment. *p < 0.05, two-way ANOVA.
s they migrate along radial glia (in red) to the superficial CP. Bins used for
CP and VZ. MZ, marginal zone; CP, cortical plate; IZ, intermediate zone; SVZ,
inations of) the indicated DNA constructs and siRNAs. At E16.5, brains were
bins) in the cortex at E16.5, two days after in utero electroporation. Color-coded
es were performed by Mann-WhitneyU test. *p < 0.05; **p < 0.01; ***p < 0.001.
sion in growth cones of E14.5 cortical neurons transfected with the indicated
M. Scale bars represent 50 mm (A), 100 mm (D), and 10 mm (H). See also Figures
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and the disassembly of ligand-receptor complexes (Bai and
Pfaff, 2011). These effects require tight control of the proteolytic
actions of ADAMs so as to prevent premature cleavage.
Numerous molecular mechanisms have been reported for
ADAM regulation in non-neuronal cell types, and these affect
ADAM expression, activity, or substrates (Blobel, 2005; Scheller
et al., 2011; Weber and Saftig, 2012). In contrast, much less is
known about ADAM regulation in neurons. Here, we identify a
unique regulatory mechanism for ADAMs by showing that Lrig2
negatively controls ADAM-mediated receptor shedding through
substrate interactions in neurons. Our data indicate that Lrig2
binds Neogenin and thereby inhibits shedding of this receptor
by ADAM17. Intriguingly, the Neogenin ligand RGMa dissociates
the Lrig2-Neogenin complex, providing ADAM17 access to Neo-
genin (Figure 7J). Although our data do not formally exclude
every previously reported mode of ADAM regulation, the most
parsimonious explanation for our results is that binding of Lrig2
to Neogenin renders Neogenin inaccessible for cleavage in the
absence of RGMa (Figure 7J).
Lrig2 Is Required for Repulsive RGMa-Neogenin
Signaling
Previous work implicated ADAM17 in RGMa-Neogenin signaling
by showing that this protease cleaves the Neogenin ectodomain
in cis and thereby terminates, rather than activates, repulsive
Neogenin signaling (Okamura et al., 2011). However, whether
this cleavage is constitutive or tightly regulated remained un-
known. Here, we show that shedding of Neogenin by ADAM17
at the growth cone is negatively controlled by Lrig2 and that
this process is, at least in part, ligand dependent. We propose
that this mechanism provides a way to limit premature Neogenin
cleavage in the presence of active proteases while retaining im-
mediate RGMa responsiveness. Previous work has shown that
proteolysis of repulsive Ephrins by ADAM10 is also regulated
by ligand-receptor binding (Hattori et al., 2000; Janes et al.,
2005). Our data are, however, conceptually distinct from
these previous results; we find that ligand binding induces the
dissociation of a substrate inhibitor, leading to shedding, rather
than inducing a new molecular recognition motif for effective
cleavage.
RGMa had been reported to inhibit the migration of different
types of neurons in vitro (Metzger et al., 2007; O’Leary et al.,Figure 7. Knockdown of Lrig2 Promotes Optic Nerve Regeneration
(A) Cell layers in the adult mouse retina. Cell bodies of retinal ganglion cells (RGC
optic nerve to the CNS. Boxed area in the GCL indicates the region shown in (B
(B) Immunohistochemistry for Neogenin, Lrig2, or ADAM17 combined with NeuN i
after optic nerve injury (ONI).
(C) Experimental setup of the ONI studies. siRNAs and/or pCAG-Neogenin-GFP e
day 14 post-injury. CTB, Alexa Fluor-555 conjugated cholera toxin subunit B.
(D) Confocal images of optic nerve axons labeled by CTB at 14 days post-injury. A
axons.
(E and F) Quantification of regenerating axons extending at specific distances from
condition. *p < 0.05; **p < 0.01, Student’s t test. Data are presented as means ±
(G) HEK293 cells were cotransfected with the indicated constructs followed by a
(H and I) HEK293 cells were co-transfected with the indicated constructs and s
indicates ADAM17-induced cleavage products.
(J) In our model, Lrig2 binds Neogenin at the cell surface to prevent premature c
dissociation of the Lrig2-Neogenin complex, which provides ADAM17 with acces
factor-like; MP, metalloprotease.
Scale bars represent 20 mm (B) and 200 mm (D). See also Figure S7.
Developm2013). Our study confirms and extends these observations by
revealing a role for RGMa-Neogenin signaling in cortical neuron
migration in vivo and by demonstrating that these RGMa-
induced effects rely on regulation of ADAM17-mediated Neoge-
nin shedding by Lrig2. Although originally identified as axon
repulsive cues, RGMs are now known to control a plethora of un-
related (non-)neuronal processes via Neogenin (Severyn et al.,
2009). In addition, Neogenin not only binds RGMs but also
functions as a cell-surface receptor for BMPs and Netrin-1 in
processes such myotube formation and endochondral bone
development (Kang et al., 2004; Zhou et al., 2010). Therefore, it
will be important to determine whether Lrig2 regulates RGMa-
Neogenin signaling events unrelated to axon growth inhibition
or Neogenin signaling in response to non-RGM ligands.
Knockdown of Lrig2 Promotes Axon Regeneration in the
Adult CNS
Intravitreal injections of Lrig2 siRNAs induced significant regen-
erative axon growth into the distal denervated portion of the
crushed optic nerve. This observation supports the exciting pos-
sibility that Lrig2 may serve as a therapeutic target for promoting
axon regeneration in the injured CNS. Our data further indicate
that Lrig2 normally inhibits axon regeneration by negatively regu-
lating ADAM17. The effect of Lrig2 knockdown on axon regener-
ation is in line with the reported role of RGMa as an inhibitor of
axon regeneration (Demicheva et al., 2015; Hata et al., 2006;
Tassew et al., 2014) and with the functional requirement for
Lrig2 in repulsive RGMa-Neogenin signaling. While it is tempting
to speculate that knockdown of Lrig2 decreases the sensitivity
of injured axons to scar-tissue-associated RGMa and thereby
promotes regeneration, it should be noted that although
Neogenin and Lrig2 siRNAs induced a similar reduction in RGC
gene expression in vivo, a far larger number of regenerating
optic nerve fibers was observed following Lrig2 knockdown.
Further, Neogenin overexpression following injection of Lrig2
siRNAs only partially rescued the effect of Lrig2 knockdown. A
plausible explanation for this apparent discrepancy is that
knockdown of Lrig2 could block the effects of multiple, distinct,
regeneration-inhibiting proteins. For example, Lrig2 binds and
reduces shedding of not only Neogenin but also Sema4D, a
repulsive cue upregulated at CNS lesion sites (Moreau-Fauvar-
que et al., 2003).s) are located in the ganglion cell layer (GCL) and send their axons through the
). INL, inner nerve layer; ONL, outer nerve layer.
mmunostaining, to visualize RGCs, on adult mouse control retinas or at 14 days
xpression vector and CTB were injected in the eye and mice were sacrificed at
sterisks indicate the distal border of the injury site. Arrows indicate regenerating
the distal end of the crush site at 14 days post-injury, as in (D). n = 6 animals per
SEM.
nti-GFP or anti-V5 pull-downs and subjected to western blot analysis.
ubjected to western blot analysis using the indicated antibodies. Arrowhead
leavage of this guidance receptor by ADAM17. Binding of RGMa induces the
s to Neogenin, resulting in ectodomain shedding. EGF-like, epidermal growth
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A General Role for Lrigs in Membrane Receptor
Shedding?
Despite reported neuronal expression, how Lrigs contribute to
nervous system development and function is poorly understood.
Lrig1 negatively regulates glial cell-line-derived neurotrophic
factor (GDNF)-induced neurite growth in vitro by binding the
GDNF receptor Ret (Ledda et al., 2008). In addition, sensory
innervation of the cochlea is disrupted in Lrig1:Lrig2 double-
knockout mice, hinting at axonal defects (Del Rio et al., 2013).
Our data extend these findings by revealing a unique neuronal
function for the poorly characterized Lrig family member Lrig2
and by showing that Lrigs regulate cellular responses not only
to chemotrophic growth factors (e.g., EGF, GDNF) but also to
chemotropic guidance cues (RGMa). This new insight is inter-
esting in light of the identification of LRIG2mutations as a cause
of urofacial syndrome (UFS), a congenital autosomal-recessive
disorder characterized by aberrant urinary bladder innervation
(Stuart et al., 2013). How UFS mutations affect Lrig2 function is
unknown, but it is tempting to speculate that they impair guid-
ance of Lrig2-positive axons that target the bladder.
Lrigs act through different molecular mechanisms to control
growth factor receptors. Lrigs enhance receptor degradation,
inhibit ligand-receptor interactions, and recruit receptors to lipid
rafts (e.g., Gur et al., 2004; Laederich et al., 2004; Ledda et al.,
2008; Wong et al., 2012). Our study demonstrates an additional
level of complexity of Lrig-dependent receptor regulation by
identifying Lrig2 as an inhibitor of receptor ectodomain shed-
ding. Several growth factor receptors, such as Met and ErbB4,
are Lrig binding partners and ADAM substrates (Blobel, 2005;
Scheller et al., 2011). This raises the intriguing possibility that
ectodomain shedding represents an additional mechanism
through which Lrigs control growth factor receptors. However,
our work and that of others indicate that the role of Lrigs is not
restricted to growth factor receptors. In C. elegans, sma-10/
Lrig binds BMP receptors, while Lrig3 modulates Wnt signaling
in Xenopus (Gumienny et al., 2010; Zhao et al., 2008). Further-
more, we report here that Lrig2 inhibits shedding of several fac-
tors (Neogenin, NCAM1, and Sema4D) that serve important roles
in embryonic development and immune function (Maness and
Schachner, 2007; Suzuki et al., 2008) and additionally that all
three Lrigs can bind Neogenin and inhibit Neogenin ectodomain
shedding (Figures S7H–S7J). This wide array of Lrig binding part-
ners with diverse functions suggests that Lrig-dependent regula-
tion of ectodomain shedding may be a common mechanism in
normal physiology and disease.
In conclusion, our findings highlight an important role for Lrigs
in neurons and unveil a unique mechanism that negatively
controls ADAM protease function. The regulatory mechanism
described here may provide new ways to understand or manip-
ulate other cleavage events mediated by ADAMs with roles in
development, physiology, and disease.
EXPERIMENTAL PROCEDURES
Mice
Animal use and care was in accordance with institutional and national guide-
lines (Dierexperimentencommissie). For IUE, mouse embryos were injected
with (combinations of) shRNAs, siRNAs, and DNA vectors together with
pCAG-GFP. Motor cortices were targeted by electroporation with an ECM
830 Electro-Square-Porator (Harvard Apparatus) set to five unipolar pulses550 Developmental Cell 35, 537–552, December 7, 2015 ª2015 Elsevof 50 ms at 30 V (950-ms interval). Embryos were placed back into the
abdomen, and abdominal muscles and skin were sutured separately. Embryos
were collected at E16.5, and heads were fixed in 4% paraformaldehyde (PFA)
and submerged in 30% sucrose. Timed-pregnant mice, optic nerve injury,
and other animal procedures are described in Supplemental Experimental
Procedures.
Immunolabeling, In Situ Hybridization, and Biochemical
Experiments
Nonradioactive in situ hybridization and immunohistochemistry were per-
formed as described previously (Schmidt et al., 2014). Western blotting, immu-
noprecipitation, and mass spectrometry were as described previously (Groen
et al., 2013). For Rho pull-down assays, cells were lysed in lysis buffer followed
by centrifugation at 4C at 15,000 rpm for 10min. To collect active Rho protein,
supernatants were incubated with 50 mg GST-tagged Rho-binding domain
(RBD) of rhotekin beads at 4C for 45 min. The beads were washed four times
with lysis buffer and subjected to SDS-PAGE followed by western blotting us-
ing anti- RhoA antibody. Whole-cell lysates were also subjected to western
blotting for total RhoA. ELISAs were performed as described previously (Oka-
mura et al., 2011). In brief, mouse Neogenin-ECD-Fc (0.005–2.0 mg/ml; R&D
Systems) diluted in 0.1% BSA/PBS was added to 96-well ELISA microplates
(Thermo Fisher Scientific) coated with 0.5 mg/ml BSA or 0.5 mg/ml recombinant
ADAM17 (R&D Systems). To examine the effect of Lrig2, Neogenin-ECD-Fc
was pre-incubated with 5.0 mg/ml BSA or 5.0 mg/ml Lrig2-ECD purified from
HEK293 cells in PBS, before addition to ADAM17-coated ELISA plates. Two
hours after incubation at room temperature, plates were washed and diluted,
and anti-Neogenin (1:1,000; R&D Systems) or anti-Fc antibody (1:1,000;
Sigma) was added. Horseradish peroxidase (HRP)-conjugated secondary
antibodies, a substrate reagent pack, and stop solutions (R&D Systems)
were used for detection. The absorbance at 450 nm was measured. To
biochemically assess receptor cell-surface expression or internalization,
N1E-115 cells were incubated with EZ-Link Sulfo-NHS-Biotin or EZ-Link
Sulfo-NHS-SS-Biotin, respectively, and subjected to western blot analysis.
For more details, please see Supplemental Experimental Procedures.
Cell Culture
Dissociated neuron cultures were prepared and transfected with siRNAs or
DNA constructs as described previously (Van Battum et al., 2014). Growth
cone collapse assays were performed on transfected P0 cortical neurons at
1 day in vitro using 2 mg/ml RGMa or control protein (Hata et al., 2006). For
CHO cell layer assays, dissociated cortical neurons were electroporated and
cultured for 4 days on confluent layers of CHO-K1 (control) or CHO-RGMa
cells. For more details, please see Supplemental Experimental Procedures.
Quantification and Statistics Methods
Statistical analyses were performed using GraphPad Prism 6 software using
the Student’s t test or one- or two-way ANOVA followed by Dunnett’s or
Tukey-Kramer’s test. All data were derived from at least three independently
performed experiments, unless stated otherwise. Data are expressed as
mean ± SEM, and significance was defined as p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2015.11.008.
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